Jason Mouabbi, Breast Medical Oncologist at the MD Anderson Cancer Centre, shared on X/Twitter:

“Exciting news from The Oncologist Journal following the impactful San Antonio Breast Cancer Symposium 2023. Our recent MD Anderson Cancer Center publication addresses a pivotal question: In the era of Antibody Drug Conjugates (ADCs), where patients must have received ≥1 prior chemotherapy agent, should capecitabine or a taxane be utilized for invasive lobular carcinoma (ILC) patients?

Our compelling findings strongly advocate for capecitabine’s superiority: 8.8 vs 5.0 months HR 0.63, P< .001.

Delving deeper, our multivariate analyses unveil key insights—favorable Progression-free survival (PFS) and Overall survival (OS) with fewer metastatic sites and increased lines of prior Essential thrombocythaemia (ET). Notably, our study sheds light on racial disparities; Black patients face challenging OS outcomes compared to their White counterparts (HR 2.46; P = .001).

Explore the full details here.”

Source: Jason Mouabbi/X